FDA-cleared profile

Rayvolve LN

AZmed · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Second-reader support for radiologists reviewing adult digital AP or PA chest radiographs, with suspected pulmonary nodules in the 6-30 mm range marked for review.

Clinical role
Adjunctive second reader for radiologists; it is not a substitute for professional interpretation.
Images and patients
X-ray/Radiography · Chest/Lung
Key limitation
Keep in mind: The product is adjunctive and cannot replace radiologist review. The cleared input is adult frontal AP/PA digital chest radiography; performance and applicability outside that scope were not established here.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Second-reader support for radiologists reviewing adult digital AP or PA chest radiographs, with suspected pulmonary nodules in the 6-30 mm range marked for review.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/Lung Input: Adult frontal AP or PA chest radiographs acquired on digital radiography systems and received through DICOM.
  • Who uses it?Intended users: Radiologists and other qualified healthcare professionals interpreting adult digital chest radiographs.
  • What does the software produce?Output: Marked suspected pulmonary nodules on the processed image, with the original image presented first and the processed image next in the described workflow.
  • What is its most important limitation?Key limitation: The product is adjunctive and cannot replace radiologist review. The cleared input is adult frontal AP/PA digital chest radiography; performance and applicability outside that scope were not established here.

Clinical takeaway. Clinical role: Second-reader support for radiologists reviewing adult digital AP or PA chest radiographs, with suspected pulmonary nodules in the 6-30 mm range marked for review.

Evidence takeaway. Evidence from the reviewed source record: In the FDA-described standalone test of 2,181 radiographs, sensitivity was 0.8847, specificity was 0.8294 and AUC was 0.8408. In a separate 400-case MRMC study, the FDA table reports AUC improvement from 0.8071 unaided to 0.8583 aided, sensitivity from 0.7975 unaided to 0.8935 aided, and specificity from 0.8235 unaided to 0.8510 aided. These are exact-submission study results and not current family claims.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Second-reader support for radiologists reviewing adult digital AP or PA chest radiographs, with suspected pulmonary nodules in the 6-30 mm range marked for review.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Adjunctive second reader for radiologists; it is not a substitute for professional interpretation.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Adult frontal AP or PA chest radiographs acquired on digital radiography systems and received through DICOM.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Marked suspected pulmonary nodules on the processed image, with the original image presented first and the processed image next in the described workflow.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Healthcare radiology services using digital adult frontal chest radiography.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Radiologists and other qualified healthcare professionals interpreting adult digital chest radiographs.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The product is adjunctive and cannot replace radiologist review. The cleared input is adult frontal AP/PA digital chest radiography; performance and applicability outside that scope were not established here.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
In the FDA-described standalone test of 2,181 radiographs, sensitivity was 0.8847, specificity was 0.8294 and AUC was 0.8408. In a separate 400-case MRMC study, the FDA table reports AUC improvement from 0.8071 unaided to 0.8583 aided, sensitivity from 0.7975 unaided to 0.8935 aided, and specificity from 0.8235 unaided to 0.8510 aided. These are exact-submission study results and not current family claims.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
In the FDA-described standalone test of 2,181 radiographs, sensitivity was 0.8847, specificity was 0.8294 and AUC was 0.8408. In a separate 400-case MRMC study, the FDA table reports AUC improvement from 0.8071 unaided to 0.8583 aided, sensitivity from 0.7975 unaided to 0.8935 aided, and specificity from 0.8235 unaided to 0.8510 aided. These are exact-submission study results and not current family claims.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
0.8847
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Standalone test sensitivity; see evidence.metrics for the stated population and sample size.

Reported specificity
0.8294
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Standalone test specificity; see evidence.metrics for the stated population and sample size.

Standalone test sensitivity

0.8847 proportion

  • EndpointSensitivity for suspected pulmonary nodule detection
  • Population2,181 adult frontal digital chest radiographs in the FDA-described standalone test
  • Tested versionRayvolve LN configuration submitted in K243831

Standalone test specificity

0.8294 proportion

  • EndpointSpecificity for suspected pulmonary nodule detection
  • Population2,181 adult frontal digital chest radiographs in the FDA-described standalone test
  • Tested versionRayvolve LN configuration submitted in K243831

Standalone test AUC

0.8408 area under ROC curve

  • EndpointAUC for suspected pulmonary nodule detection
  • Population2,181 adult frontal digital chest radiographs in the FDA-described standalone test
  • Tested versionRayvolve LN configuration submitted in K243831

MRMC AUC without assistance

0.8071 area under ROC curve

  • EndpointUnaided reader AUC
  • Population400-case MRMC reader study
  • Tested versionRayvolve LN configuration submitted in K243831

MRMC AUC with assistance

0.8583 area under ROC curve

  • EndpointAided reader AUC
  • Population400-case MRMC reader study
  • Tested versionRayvolve LN configuration submitted in K243831

MRMC sensitivity without assistance

0.7975 proportion

  • EndpointUnaided reader sensitivity
  • Population400-case MRMC reader study
  • Tested versionRayvolve LN configuration submitted in K243831

MRMC sensitivity with assistance

0.8935 proportion

  • EndpointAided reader sensitivity
  • Population400-case MRMC reader study
  • Tested versionRayvolve LN configuration submitted in K243831

MRMC specificity without assistance

0.8235 proportion

  • EndpointUnaided reader specificity
  • Population400-case MRMC reader study
  • Tested versionRayvolve LN configuration submitted in K243831

MRMC specificity with assistance

0.851 proportion

  • EndpointAided reader specificity
  • Population400-case MRMC reader study
  • Tested versionRayvolve LN configuration submitted in K243831

Rayvolve LN standalone test

  • DesignRetrospective standalone diagnostic performance test described in the FDA 510(k) summary
  • Population2,181 adult frontal digital chest radiographs with suspected pulmonary nodules
  • Scopeexact submission
  • Tested versionRayvolve LN configuration submitted in K243831
  • Samplen=2181
  • IndependenceSponsor or vendor study

K243831

FDA reports sensitivity 0.8847, specificity 0.8294 and AUC 0.8408.

Rayvolve LN MRMC reader study

  • DesignTwo-session multi-reader multi-case study with sessions at least one month apart
  • Population400 chest radiographs read by radiologist participants
  • Scopeexact submission
  • Tested versionRayvolve LN configuration submitted in K243831
  • Samplen=400
  • IndependenceSponsor or vendor study

K243831

FDA table headings report unaided-to-aided improvement: AUC 0.8071 to 0.8583, sensitivity 0.7975 to 0.8935 and specificity 0.8235 to 0.8510. The source-reported confidence intervals are not reproduced here.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult frontal AP or PA chest radiographs acquired on digital radiography systems and received through DICOM.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K243831: Rayvolve LN

  2. Routing

    Source context, not route validation: Standalone deep-learning software connected to a local radiology network through a DICOM node and PACS; the processed image is returned as a DICOM image for review.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K243831: Rayvolve LN

  3. AI processing

    Source context, not route validation: The FDA summary describes on-premises or cloud-platform deployment connected to the local radiology network, with DICOM-node/PACS interaction.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K243831: Rayvolve LN

  4. Returned objects

    Source context, not route validation: Marked suspected pulmonary nodules on the processed image, with the original image presented first and the processed image next in the described workflow.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K243831: Rayvolve LN

  5. Viewer/worklist/report

    Unresolved route: Marked suspected pulmonary nodules on the processed image, with the original image presented first and the processed image next in the described workflow.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K243831: Rayvolve LN

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA summary describes on-premises or cloud-platform deployment connected to the local radiology network, with DICOM-node/PACS interaction.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
Standalone deep-learning software connected to a local radiology network through a DICOM node and PACS; the processed image is returned as a DICOM image for review.
  • Exact FDA submission
  • Checked 2026-09-07

DICOM node and PACS workflow

The cleared configuration connects to a DICOM node and PACS, presents the original image first and then a processed image.

exact submission · checked 2026-09-07

On-premises or cloud-connected family deployment

AZmed describes the Rayvolve suite as radiology AI that can be integrated into clinical imaging workflows; the current page does not establish the exact hosting, service levels or version for K243831.

product family · checked 2026-09-06
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243831
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Chest/Lung
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-03-26
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-07Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public price or quote for Rayvolve LN was reviewed.

  • Pricing model: Not verified - checked 2026-09-07 - Exact FDA submission

    License, per-study, subscription and implementation terms were not established.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "AZmed Rayvolve reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-07 - Exact FDA submission

    The reviewed sources do not establish exact-release security controls, retention or assurance documentation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA 510(k) K243831: Rayvolve LN

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, purpose, clinicalUse, modality, anatomy, workflowRole, intendedUsers, careSetting, input, output, limitations, integration, deployment, reportedSensitivity, reportedSpecificity, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Rayvolve LN model card (K243831)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. AI Radiology: Fracture Detection, Chest, Measure, BoneAge

    AZmed - Accessed 2026-09-06

    Scope: productFamilyContext, implementationCapabilities

Research history

  1. K243831 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K201560

Auto Lung Nodule Detection

Samsung Electronics Co.,Ltd.

Authorized purpose: Identifies and marks suspected pulmonary nodules 10-30 mm on adult PA chest radiographs as a second-reader aid.

Modality
X-ray/Radiography
Anatomy
Chest/Lung
Decision
2021-08-31
FDA-cleared K243808

Rayvolve PTX-PE

AZmed

Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.

Modality
X-ray/Radiography
Anatomy
Chest/Lung
Decision
2025-03-21
FDA-cleared K241620

ChestView US

Gleamer SAS

Authorized purpose: Concurrent reading aid for adult frontal and lateral chest radiographs, marking suspected nodules, pleural-space abnormalities, mediastinal/hilar abnormalities and consolidations.

Modality
X-ray/Radiography
Anatomy
Chest/Lung
Decision
2025-02-27

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history